Alnylam (ALNY) Surges 6.0%: Is This an Indication of Further Gains?
Alnylam (ALNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the pricing of its previously announced private o...
Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?
Alnylam's strong drug sales and advancing partnerships with Regeneron and Roche highlight key growth drivers in the quarters ahead.
Alnylam Pharmaceuticals: Amvuttra's Launch And Ongoing Clinical Progress Are Positives
Alnylam's strong clinical productivity and commercial execution continue to support my view that it's one of the best all-around biotechs, with a robust revenue and earnings outlook. Amvuttra's TTR...
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran's Long-Term Cardiovascular Benefit in ATTR-CM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AM...
Earnings Estimates Rising for Alnylam (ALNY): Will It Gain?
Alnylam Pharmaceuticals (ALNY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up
Alnylam stock jumps 15% after a surprise Q2 profit, driven by soaring Amvuttra sales and raised 2025 revenue guidance.
3 High-Flying Stocks That Could Soar Even More
Many investors love the "big mo." That's short for "big momentum.
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Christine Lindenboom – Chief Corporate Communications Officer Yvonne Greens...
Alnylam Delivers a Big Q4 Earnings Beat
Alnylam Pharmaceuticals (ALNY 0.21%), known for its innovative RNA interference (RNAi) therapeutics, released its fourth-quarter earnings on Feb. 13. The company's non-GAAP earnings per share (EPS)...
Alnylam Pharmaceuticals (ALNY) Beats Q4 Earnings and Revenue Estimates
Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.21 per share. This compares to loss of $1.10 per share a yea...
Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?
We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week.
Here's Why Alnylam Pharmaceuticals (ALNY) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Alnylam Pharmaceuticals: Commercialization And Early-Stage Studies Are Likely To Drive 2025
Alnylam Pharmaceuticals: Commercialization And Early-Stage Studies Are Likely To Drive 2025
Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Singl...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the presentation of new results from its Phase 1 study of nuc...
Related Companies